Hydrophilic, Pro-Drug Analogues of T138067 Are Efficacious in Controlling Tumor Growth In Vivo and Show a Decreased Ability To Cross the Blood Brain Barrier
- 14 September 2001
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 44 (22) , 3599-3605
- https://doi.org/10.1021/jm000478d
Abstract
The novel anticancer compound T138067 is an irreversible inhibitor of tubulin polymerization. Amides 3−6 were synthesized using standard methodologies and determined to be significantly less lipophilic than T138067 based on logP calculations. Tubulin polymerization and [3H]-T138067 competition assays revealed that these amides are pro-drugs for parent aniline 2. Amides 3−5 showed no detectable signs of crossing the blood brain barrier, while amide 6 was found in extremely small amounts (12 ng/g of brain tissue). Aniline 2, which was formed in vivo from these amides, was found in significantly smaller amounts (approximately 20 to >5000 times) in the brain than when 2 was administered directly. The in vivo efficacy of amide 6 approached that of T138067 and was better tolerated when administered to athymic nude mice bearing MX-1 human mammary tumor xenografts.Keywords
This publication has 8 references indexed in Scilit:
- Novel halogenated sulfonamides inhibit the growth of multidrug resistant MCF-7/ADR cancer cellsBioorganic & Medicinal Chemistry Letters, 1999
- Selective, covalent modification of β-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumorsProceedings of the National Academy of Sciences, 1999
- Use of Onium Salt-Based Coupling Reagents in Peptide Synthesis1The Journal of Organic Chemistry, 1998
- Syntheses and antitumor activity of cis-restricted combretastatins: 5-Membered heterocyclic analoguesBioorganic & Medicinal Chemistry Letters, 1998
- Novel antineoplastic agents with efficacy against multidrug resistant tumor cellsBioorganic & Medicinal Chemistry Letters, 1998
- Novel Combretastatin Analogues Effective against Murine Solid Tumors: Design and Structure−Activity RelationshipsJournal of Medicinal Chemistry, 1998
- Phase I trial and pharmacokinetics of the tubulin inhibitor 1069C85--a synthetic agent binding at the colchicine site designed to overcome multidrug resistanceBritish Journal of Cancer, 1997
- The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeuticsPharmacology & Therapeutics, 1991